Resources

The latest results from a clinical trial with a SGLT Inhibitor demonstrates the major opportunity for this unique molecule to have an impact on treating diabetes. But even with this new class of drugs to fight diabetes, unless the patient is educated, they are still doomed for failure.  

Wide sections of the Southeast, Appalachia, and some tribal lands in the West and Northern Plains have the nation′s highest rates of obesity and diabetes, according to estimates released last week by the Centers for Disease Control and Prevention. What are the percentages in your neighborhood?

Combination therapy of a statin plus niacin is superior to that of a statin plus ezetimibe among long-term, high-risk statin users, according to research reported at the American Heart Association (AHA) Scientific Sessions 2009.

Patients whose hypertension is managed by a physician-pharmacist team have lower blood pressure levels and are more likely to reach goals for blood pressure control than those treated without this collaborative approach, according to a report in JAMA.

Consumption of alcohol in almost any quantity is associated with a nearly one-third reduction in the incidence of coronary heart disease (CHD) — at least in men, a large Spanish study confirmed.

Spherix, Inc., a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, announced positive interim Phase 3 clinical results for the planned review of the NEET (Naturlose, [D-tagatose]).

Hyperuricemia in young adults was linked to a significant, roughly twofold increased risk for developing Type 2 diabetes during the subsequent 13 years in an observational study with nearly 5,000 participants.

To meet the changing needs of people affected by this growing epidemic, the American Diabetes Association (ADA) has launched a completely redesigned https://www.diabetes.org in English and Spanish.

Obese patients with uncontrolled Type 2 diabetes who were treated with an investigational endoscopic duodenal-jejunal bypass liner achieved near normalization of glycemic control in one week, as compared with a sham group.

After one year of continuous glucose monitoring, HbA1c was sustained at 6.4% in patients with Type 1 diabetes who had HbA1c less than 7% at baseline. However, children and adolescents were less likely to use continuous glucose monitoring on a daily basis compared with adults.